Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1956 1
1961 5
1962 6
1963 10
1964 10
1965 8
1966 8
1967 14
1968 16
1969 13
1970 16
1971 12
1972 15
1973 8
1974 13
1975 6
1976 16
1977 18
1978 12
1979 20
1980 21
1981 11
1982 20
1983 30
1984 13
1985 23
1986 28
1987 34
1988 51
1989 46
1990 41
1991 35
1992 34
1993 37
1994 44
1995 51
1996 71
1997 60
1998 59
1999 85
2000 79
2001 59
2002 65
2003 89
2004 103
2005 111
2006 108
2007 109
2008 105
2009 106
2010 104
2011 108
2012 136
2013 95
2014 91
2015 129
2016 133
2017 144
2018 180
2019 174
2020 196
2021 207
2022 25
Text availability
Article attribute
Article type
Publication date

Search Results

3,361 results
Results by year
Filters applied: . Clear all
Page 1
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H. Muraoka D, et al. Among authors: fujii k. J Clin Invest. 2019 Mar 1;129(3):1278-1294. doi: 10.1172/JCI97642. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30628894 Free PMC article.
Gene- and Species-Specific Hox mRNA Translation by Ribosome Expansion Segments.
Leppek K, Fujii K, Quade N, Susanto TT, Boehringer D, Lenarčič T, Xue S, Genuth NR, Ban N, Barna M. Leppek K, et al. Among authors: fujii k. Mol Cell. 2020 Dec 17;80(6):980-995.e13. doi: 10.1016/j.molcel.2020.10.023. Epub 2020 Nov 16. Mol Cell. 2020. PMID: 33202249 Free PMC article.
Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity.
Tanaka S, Ise W, Inoue T, Ito A, Ono C, Shima Y, Sakakibara S, Nakayama M, Fujii K, Miura I, Sharif J, Koseki H, Koni PA, Raman I, Li QZ, Kubo M, Fujiki K, Nakato R, Shirahige K, Araki H, Miura F, Ito T, Kawakami E, Baba Y, Kurosaki T. Tanaka S, et al. Among authors: fujii k. Nat Immunol. 2020 Aug;21(8):950-961. doi: 10.1038/s41590-020-0700-y. Epub 2020 Jun 22. Nat Immunol. 2020. PMID: 32572241
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.
Leppek K, Byeon GW, Kladwang W, Wayment-Steele HK, Kerr CH, Xu AF, Kim DS, Topkar VV, Choe C, Rothschild D, Tiu GC, Wellington-Oguri R, Fujii K, Sharma E, Watkins AM, Nicol JJ, Romano J, Tunguz B, Participants E, Barna M, Das R. Leppek K, et al. Among authors: fujii k. bioRxiv. 2021 Mar 30:2021.03.29.437587. doi: 10.1101/2021.03.29.437587. Preprint. bioRxiv. 2021. PMID: 33821271 Free PMC article.
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN. Uemura H, et al. Among authors: fujii k. Int J Urol. 2021 Mar;28(3):280-287. doi: 10.1111/iju.14447. Epub 2020 Dec 8. Int J Urol. 2021. PMID: 33295007 Clinical Trial.
Author's reply.
Ishibuchi K, Fujii K. Ishibuchi K, et al. Among authors: fujii k. J Cardiol. 2021 Feb;77(2):207. doi: 10.1016/j.jjcc.2020.09.006. Epub 2020 Oct 17. J Cardiol. 2021. PMID: 33082058 No abstract available.
Effects of sclerostin antibody on bone healing.
Mihara A, Yukata K, Seki T, Iwanaga R, Nishida N, Fujii K, Nagao Y, Sakai T. Mihara A, et al. Among authors: fujii k. World J Orthop. 2021 Sep 18;12(9):651-659. doi: 10.5312/wjo.v12.i9.651. eCollection 2021 Sep 18. World J Orthop. 2021. PMID: 34631449 Free PMC article. Review.
Microcystic Adnexal Carcinoma with Xanthomatous Reaction.
Fujii K, Arimura A, Ibusuki A, Uchida Y, Kanekura T. Fujii K, et al. Acta Derm Venereol. 2021 Apr 26;101(4):adv00436. doi: 10.2340/00015555-3792. Acta Derm Venereol. 2021. PMID: 33734422 Free article. No abstract available.
Minimal Change Disease Associated With Durvalumab.
Toda MG, Fujii K, Kato A, Yoshifuji A, Komatsu M, Amino Y, Kitazono S, Hashiguchi A, Ryuzaki M. Toda MG, et al. Among authors: fujii k. Kidney Int Rep. 2021 Sep 1;6(10):2733-2734. doi: 10.1016/j.ekir.2021.08.021. eCollection 2021 Oct. Kidney Int Rep. 2021. PMID: 34622115 Free PMC article. No abstract available.
3,361 results